• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

轴性脊柱关节炎的发病率和患病率:文献中的方法学挑战和差距。

Incidence and prevalence of axial spondyloarthritis: methodologic challenges and gaps in the literature.

机构信息

UCB Pharma, Raleigh, USA.

Oregon Health and Science University, Portland, USA.

出版信息

Clin Exp Rheumatol. 2018 Mar-Apr;36(2):263-274. Epub 2017 Nov 14.

PMID:29148402
Abstract

OBJECTIVES

The incidence and prevalence of axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic (nr-)axSpA, have been investigated in multiple populations, though there is a paucity of population-level data. Here, we identify population-based studies in AS and nr-axSpA, and describe the methodologic challenges in conducting these, outlining potential reasons for disparate incidence and prevalence estimates.

METHODS

PubMed and Embase were searched for population-based studies providing incidence and prevalence rates, published in English from 1 Jan 2000-30 Jun 2015. Extracted information included incidence/prevalence rates, geographical population, study design, data source, case definition, age/gender, and classification criteria used.

RESULTS

Of 2,148 articles identified, 19, from 15 countries, fulfilled eligibility criteria. Incidence rates per 100,000 patient-years were reported in 4 AS studies and varied from 0.4 (Iceland) to 15.0 (Canada). Reported AS prevalence rates per 100,000 persons also showed considerable variation (16 studies: 6.5 [Japan] to 540.0 [Turkey]). Only 3 axSpA and no nr-axSpA prevalence rates were reported. Considerable variation was seen in the methodology used to estimate incidence and prevalence rates, e.g. screening method, study design, and classification criteria. Although the prevalence of AS is known to vary by HLA-B27 status, only 4 studies reported this genetic marker.

CONCLUSIONS

There is an unmet need for future studies to use consistent methodology, capture all relevant information (including HLA-B27 positivity), and investigate under-reported populations (e.g. nr-axSpA; southern hemisphere countries) to estimate the population burden of axSpA. Future studies should aim to address data gaps to provide accurate incidence/prevalence estimates for the global axSpA population.

摘要

目的

轴性脊柱关节炎(axSpA)的发病率和患病率,包括强直性脊柱炎(AS)和非放射学(nr-)axSpA,已经在多个人群中进行了研究,尽管人群水平的数据很少。在这里,我们确定了 AS 和 nr-axSpA 的基于人群的研究,并描述了进行这些研究的方法学挑战,概述了发病率和患病率估计值差异的潜在原因。

方法

在 PubMed 和 Embase 中搜索了 2000 年 1 月 1 日至 2015 年 6 月 30 日发表的基于人群的研究,提供发病率和患病率率,用英文发表。提取的信息包括发病率/患病率率、地理人群、研究设计、数据源、病例定义、年龄/性别和使用的分类标准。

结果

在 2148 篇文章中,有 19 篇来自 15 个国家,符合入选标准。有 4 项 AS 研究报告了每 10 万患者年的发病率,发病率从冰岛的 0.4 到加拿大的 15.0 不等。也有 16 项研究报告了每 10 万人的 AS 患病率存在很大差异(日本为 6.5,土耳其为 540.0)。仅报告了 3 项 axSpA 和无 nr-axSpA 患病率。用于估计发病率和患病率的方法学存在很大差异,例如筛选方法、研究设计和分类标准。尽管 AS 的患病率已知因 HLA-B27 状态而异,但只有 4 项研究报告了这种遗传标记。

结论

未来的研究需要使用一致的方法,收集所有相关信息(包括 HLA-B27 阳性),并调查报告不足的人群(例如 nr-axSpA;南半球国家),以估计 axSpA 的人群负担。未来的研究应旨在解决数据差距,为全球 axSpA 人群提供准确的发病率/患病率估计。

相似文献

1
Incidence and prevalence of axial spondyloarthritis: methodologic challenges and gaps in the literature.轴性脊柱关节炎的发病率和患病率:文献中的方法学挑战和差距。
Clin Exp Rheumatol. 2018 Mar-Apr;36(2):263-274. Epub 2017 Nov 14.
2
HLA B27 antigen in Middle Eastern and Arab countries: systematic review of the strength of association with axial spondyloarthritis and methodological gaps.中东和阿拉伯国家的人类白细胞抗原B27抗原:与轴性脊柱关节炎关联强度的系统评价及方法学差距
BMC Musculoskelet Disord. 2017 Jun 29;18(1):280. doi: 10.1186/s12891-017-1639-5.
3
Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.强直性脊柱炎与非放射学轴性脊柱关节炎:肿瘤坏死因子抑制剂疗效及HLA - B27状态影响的比较。一项来自全国性DANBIO注册研究的观察性队列研究。
J Rheumatol. 2017 Jan;44(1):59-69. doi: 10.3899/jrheum.160958. Epub 2016 Dec 1.
4
HLA-B27 prevalence in axial spondyloarthritis patients and in blood donors in a Lebanese population: Results from a nationwide study.黎巴嫩人群中轴型脊柱关节炎患者及献血者的HLA - B27患病率:一项全国性研究的结果
Int J Rheum Dis. 2019 Apr;22(4):708-714. doi: 10.1111/1756-185X.13487. Epub 2019 Feb 6.
5
Heterogeneity of axial spondyloarthritis: genetics, sex and structural damage matter.轴向型脊柱关节炎的异质性:遗传学、性别和结构损伤起重要作用。
RMD Open. 2022 May;8(1). doi: 10.1136/rmdopen-2022-002302.
6
Comparison of clinical characteristics between adult-onset and juvenile-onset non-radiographic axial spondyloarthritis in Chinese patients: results from the COCAS cohort.中国患者成人发病和青少年发病的非放射学中轴型脊柱关节炎的临床特征比较:来自 COCAS 队列的研究结果。
Eur J Med Res. 2023 Sep 28;28(1):388. doi: 10.1186/s40001-023-01387-x.
7
Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis.强直性脊柱炎与非放射学中轴型脊柱关节炎外周及关节外疾病的患病率:一项荟萃分析。
Arthritis Res Ther. 2016 Sep 1;18(1):196. doi: 10.1186/s13075-016-1093-z.
8
Axial Spondyloarthritis in Japan.日本的轴性脊柱关节炎
Curr Rheumatol Rep. 2022 May;24(5):149-155. doi: 10.1007/s11926-022-01068-4. Epub 2022 Apr 5.
9
The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study.风湿病科门诊炎性背痛患者中无放射学表现的轴性脊柱关节炎的患病率及临床特征:一项多国多中心研究
Arthritis Res Ther. 2016 Jun 7;18(1):132. doi: 10.1186/s13075-016-1027-9.
10
Ankylosing spondylitis and nonradiographic axial spondyloarthritis: part of a common spectrum or distinct diseases?强直性脊柱炎和非放射学中轴型脊柱关节炎:共同谱的一部分还是不同的疾病?
J Rheumatol. 2013 Dec;40(12):2038-41. doi: 10.3899/jrheum.130588. Epub 2013 Nov 1.

引用本文的文献

1
Gut microbiota and ankylosing spondylitis: current insights and future challenges.肠道微生物群与强直性脊柱炎:当前见解与未来挑战。
Microb Cell. 2025 Aug 25;12:210-230. doi: 10.15698/mic2025.08.857. eCollection 2025.
2
Associations between comorbidities and patient-reported outcomes in axial spondyloarthritis: data from a single-center real-world cohort.中轴型脊柱关节炎共病与患者报告结局之间的关联:来自单中心真实世界队列的数据。
Clin Rheumatol. 2025 May 7. doi: 10.1007/s10067-025-07452-6.
3
Diversity in Axial Spondyloarthritis Drug Trials: Enrollment by Sex, Race, Ethnicity, and Geographic Region.
轴性脊柱关节炎药物试验中的多样性:按性别、种族、民族和地理区域进行入组
J Rheumatol. 2025 Mar 15. doi: 10.3899/jrheum.2024-1013.
4
A self-management intervention for newly diagnosed with inflammatory arthritis: a randomized controlled feasibility and fidelity study.一项针对新诊断为炎性关节炎患者的自我管理干预措施:一项随机对照可行性与保真度研究。
Pilot Feasibility Stud. 2025 Feb 11;11(1):15. doi: 10.1186/s40814-025-01601-z.
5
Association Between Diagnostic Delay and Economic and Clinical Burden in Axial Spondyloarthritis: A Multicentre Retrospective Observational Study.轴性脊柱关节炎的诊断延迟与经济及临床负担之间的关联:一项多中心回顾性观察研究
Rheumatol Ther. 2025 Apr;12(2):255-266. doi: 10.1007/s40744-024-00742-6. Epub 2025 Jan 13.
6
Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis.托法替布治疗强直性脊柱炎2期和3期试验的综合安全性分析
Adv Rheumatol. 2024 Dec 18;64(1):87. doi: 10.1186/s42358-024-00402-x.
7
Validity and reliability of the Turkish version of Exercise Benefits/ Barriers Scale: Perceived exercise benefits and barriers of patients with different axial spondyloarthritis subtypes.《运动益处/障碍量表》土耳其语版的效度和信度:不同轴向型脊柱关节炎亚型患者的运动感知益处和障碍
Arch Rheumatol. 2024 Aug 26;39(3):447-458. doi: 10.46497/ArchRheumatol.2024.10720. eCollection 2024 Sep.
8
Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis.接受托法替尼治疗的强直性脊柱炎患者的疼痛、晨僵、疲劳和疾病活动改善时间:一项事后分析。
Arthritis Res Ther. 2024 May 24;26(1):105. doi: 10.1186/s13075-024-03313-w.
9
To be or not to B27 positive: implications for the phenotypes of axial spondyloarthritis outcomes. Data from a large multiracial cohort from the Brazilian Registry of Spondyloarthritis.是否存在 B27 阳性:对轴性脊柱关节炎结局表型的影响。来自巴西脊柱关节炎登记处的大型多民族队列研究数据。
Adv Rheumatol. 2024 Apr 26;64(1):33. doi: 10.1186/s42358-024-00372-0.
10
Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis.人群药代动力学和疗效及安全性的暴露-反应分析:乌帕替尼在中轴型脊柱关节炎患者中的应用。
Clin Transl Sci. 2024 Feb;17(2):e13733. doi: 10.1111/cts.13733.